Therapeutic Areas

Nuventra has broad and extensive experience in a multitude of therapeutic areas and understands the importance of clinical pharmacology/pharmacokinetic strategies within each area.  We also have a complete understanding of the regulatory environment associated with each therapeutic area as related to clinical pharmacology/pharmacokinetic strategies.

» Analgesia (e.g., nociceptive, neuropathic pain, breakthrough cancer pain)
» Anesthesia (e.g., neuromuscular blockers, etc.)
» Cardiovascular (e.g., anticoagulant, coagulant)
» Central Nervous System (e.g., epilepsy, depression, Parkinson’s disease, Tourette’s syndrome, and schizophrenia)
» Dermatology
» Gastrointestinal (e.g., ulcerative colitis, IBS, chronic constipation, travelers’ diarrhea, anal fissure)
» Hematology (e.g., sickle cell disease, leukemia)
» Hepatology (e.g., hepatic encephalopathy)
» Infectious disease (multiple indications)
» Inflammatory disease (e.g., rheumatoid arthritis)
» Metabolic diseases (e.g., Type 1 and Type 2 diabetes, low testosterone, etc.)
» Oncology (multiple different oncology products and indications)
» Orphan/Rare diseases (e.g., hereditary inclusion body myopathy, Niemann Pick Type C)
» Pediatric diseases (pediatric research equity act requirements)***
» Pulmonary (e.g., COPD, asthma, pulmonary hypertension, WHO Groups 1-4; PAH, IPF, ILD)
» Viral disease (e.g., HIV, hepatitis [HBV, HCV])

***Our VP of PK, Dr. Bill Wargin was the International Director of Clinical Pharmacology for Oncology, Anti-emesis & Anesthesiology at GSK. We understand and appreciate the difficulty of collecting and assessing pharmacokinetic data in oncology patients.